Reirradiation of prostate, gynaecologic and pelvic tumours, suggestions from the Recommendations Commission of the Société française de radiothérapie oncologique.

Fiche publication

Date publication

novembre 2025

Journal

Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique

Auteurs

Membres identifiés du Cancéropôle Est :
Pr ANTONI Delphine

Tous les auteurs :
Zhou Y, Escande A, Pasquier D, Chargari C, Ayadi M, Khalifa J, Antoni D, Latorzeff I, Guimas V, Vendrely V, Beddok A, Supiot S

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/41289930

Résumé

The process of reirradiation in oncology presents a distinctive set of challenges, wherein clinical decision-making is predicated on a delicate balancing act between the efficacy of the treatment and the risk of severe toxicity. Despite the paucity of randomized and prospective data, an increasing number of clinical guidelines encourage its consideration for patients with local or metastatic recurrence. While awaiting dedicated guidance from international scientific societies, the following publication is based on the guidelines and multicentre reflections of the Recommendations Commission of the Société française de radiothérapie oncologique (SFRO, the French society for radiation oncology). It addresses key questions related to reirradiation, with a particular focus on prostate, gynaecological and pelvic tumours.